NASDAQ:ASMB Assembly Biosciences (ASMB) Stock Price, News & Analysis → The AI Bottleneck No One is Talking About (From The Bull Report) (Ad) Free ASMB Stock Alerts $11.80 -0.37 (-3.04%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$11.60▼$12.1050-Day Range$9.57▼$13.5852-Week Range$7.69▼$20.04Volume9,851 shsAverage Volume31,022 shsMarket Capitalization$64.66 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Assembly Biosciences alerts: Email Address Assembly Biosciences MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside52.5% Upside$18.00 Price TargetShort InterestHealthy0.53% of Float Sold ShortDividend StrengthN/ASustainability-0.71Upright™ Environmental ScoreNews Sentiment0.02Based on 30 Articles This WeekInsider TradingAcquiring Shares$233,991 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($14.29) to ($14.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.29 out of 5 starsMedical Sector153rd out of 947 stocksPharmaceutical Preparations Industry64th out of 435 stocks 3.0 Analyst's Opinion Consensus RatingAssembly Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.00, Assembly Biosciences has a forecasted upside of 52.5% from its current price of $11.80.Amount of Analyst CoverageAssembly Biosciences has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.53% of the float of Assembly Biosciences has been sold short.Short Interest Ratio / Days to CoverAssembly Biosciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Assembly Biosciences has recently decreased by 63.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAssembly Biosciences does not currently pay a dividend.Dividend GrowthAssembly Biosciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAssembly Biosciences has received a 74.27% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for infectious diseases", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Assembly Biosciences is -0.71. Previous Next 2.2 News and Social Media Coverage News SentimentAssembly Biosciences has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Assembly Biosciences this week, compared to 24 articles on an average week.MarketBeat Follows4 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Assembly Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $233,991.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Assembly Biosciences is held by insiders.Percentage Held by InstitutionsOnly 19.92% of the stock of Assembly Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Assembly Biosciences are expected to decrease in the coming year, from ($14.29) to ($14.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assembly Biosciences is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assembly Biosciences is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssembly Biosciences has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Assembly Biosciences Stock (NASDAQ:ASMB)Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Read More ASMB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASMB Stock News HeadlinesMarch 19, 2024 | msn.comSC Refuses To Stay Himachal Pradesh Assembly Speaker Order Disqualifying Rebel Congress MLAsMarch 19, 2024 | msn.comAndhra Pradesh: Battle lines drawn in Gajuwaka Assembly seatMarch 19, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: March 19, 2024 | msn.comUofL students, faculty, staff hold rally in opposition to DEI bills in Kentucky General AssemblyMarch 18, 2024 | foxnews.comNY Assembly candidate sounds alarm on migrants' flea markets: 'Epicenter' of illegal activityMarch 18, 2024 | msn.comAssembly Democrats line up for open state Senate seatMarch 17, 2024 | msn.com"I request ECI to conduct J-K Assembly polls one month after LS elections": Ghulam Nabi AzadMarch 16, 2024 | msn.comAssembly elections in Jammu and Kashmir will be held after Lok Sabha polls: CEC Rajiv KumarMarch 19, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: March 16, 2024 | msn.comECI announces schedule for Lok Sabha polls, Assembly polls in 4 states, bypolls on 26 Assembly seatsMarch 16, 2024 | msn.comWhy no Assembly elections in Jammu and Kashmir: Farooq AbdullahMarch 16, 2024 | msn.comPak National Assembly passes resolution seeking extension in seven ordinances amid Oppn protestsMarch 16, 2024 | msn.comAssembly polls in J&K to be held as soon as possible after Lok Sabha election: CEC Rajiv KumarMarch 16, 2024 | msn.comAndhra Pradesh Assembly elections 2024: Polling dates, results and more; check full schedule hereMarch 16, 2024 | msn.comAssembly Elections 2024: Check The Polling Dates for Andhra Pradesh, Arunachal Pradesh, Sikkim, and Odisha Assembly ElectionsMarch 16, 2024 | msn.comAssembly polls in J and K to be held as soon as possible after Lok Sabha election: CEC Rajiv KumarMarch 15, 2024 | yahoo.comSome Assembly Required Season 1 Streaming: Watch & Stream Online via NetflixMarch 14, 2024 | msn.comWATCH LIVE: Gov. Youngkin provides remarks following end of 2024 Va. General Assembly SessionMarch 14, 2024 | msn.comMizoram Assembly budget session adjourned sine die, 10 bills passedMarch 14, 2024 | msn.comControversial bill that would limit transparency in government pulled by NJ AssemblyMarch 14, 2024 | msn.comLawmakers pass Senate and Assembly budgetsMarch 14, 2024 | msn.comNJ Assembly pulls controversial OPRA bill that would limit government transparencyMarch 14, 2024 | yahoo.comTake Jack Colwell's quiz about the just-completed session of the Indiana General AssemblyMarch 13, 2024 | msn.comElection Commission to decide on holding Lok Sabha, Assembly polls simultaneously in J-KMarch 13, 2024 | msn.comThe General Assembly has adjourned, next is the 'veto session'March 13, 2024 | msn.comNYS Assembly passes CO2 fracking banMarch 13, 2024 | news.yahoo.comGalesburg-area student gets first-hand look at how Illinois' General Assembly worksSee More Headlines Receive ASMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/18/2024Next Earnings (Estimated)3/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ASMB CUSIP92282210 CIK1426800 Webwww.assemblybio.com Phone(833) 509-4583Fax646-706-5101Employees68Year Founded2005Price Target and Rating Average Stock Price Target$18.00 High Stock Price Target$18.00 Low Stock Price Target$18.00 Potential Upside/Downside+52.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($17.0468) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-116.42% Return on Assets-95.89% Debt Debt-to-Equity RatioN/A Current Ratio6.96 Quick Ratio6.96 Sales & Book Value Annual Sales$6.25 million Price / Sales10.35 Cash FlowN/A Price / Cash FlowN/A Book Value$20.34 per share Price / Book0.58Miscellaneous Outstanding Shares5,480,000Free Float5,256,000Market Cap$64.66 million OptionableOptionable Beta0.56 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Jason A. Okazaki (Age 48)CEO, President & Director Comp: $869.28kDr. William E. Delaney IV (Age 52)Ph.D., Chief Scientific Officer Comp: $664.4kDr. Uri A. Lopatin M.D. (Age 52)Co-Founder and Clinical & Scientific Advisor Comp: $608.55kDr. Adam ZlotnickCo-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory BoardJeanette M BjorkquistExecutive Director of Accounting & TreasuryShannon RyanSenior Vice President of Investor Relations, Corporate Affairs & Alliance ManagementMs. Jennifer A. Troia MHRODSHRM-SCP, SPHR, Chief Human Resources OfficerDr. Nicole S. White Ph.D.Chief Manufacturing OfficerDr. Anuj Gaggar M.D.Ph.D., Chief Medical OfficerMr. Thomas E. Rollins (Age 68)Executive Officer Comp: $472.55kMore ExecutivesKey CompetitorsCumberland PharmaceuticalsNASDAQ:CPIXSol-Gel TechnologiesNASDAQ:SLGLStrongbridge BiopharmaNASDAQ:SBBPNektar TherapeuticsNASDAQ:NKTROmerosNASDAQ:OMERView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 99,092 shares on 3/11/2024Ownership: 42.684%Vanguard Group Inc.Bought 99,092 shares on 2/15/2024Ownership: 42.676%Citadel Advisors LLCBought 6,200 shares on 2/15/2024Ownership: 0.000%Northern Trust CorpBought 23,066 shares on 2/13/2024Ownership: 0.199%Simplex Trading LLCBought 200 shares on 2/2/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ASMB Stock Analysis - Frequently Asked Questions Should I buy or sell Assembly Biosciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ASMB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASMB, but not buy additional shares or sell existing shares. View ASMB analyst ratings or view top-rated stocks. What is Assembly Biosciences' stock price target for 2024? 1 analysts have issued 12-month price objectives for Assembly Biosciences' shares. Their ASMB share price targets range from $18.00 to $18.00. On average, they anticipate the company's share price to reach $18.00 in the next year. This suggests a possible upside of 52.5% from the stock's current price. View analysts price targets for ASMB or view top-rated stocks among Wall Street analysts. How have ASMB shares performed in 2024? Assembly Biosciences' stock was trading at $9.8412 at the start of the year. Since then, ASMB stock has increased by 19.9% and is now trading at $11.80. View the best growth stocks for 2024 here. Are investors shorting Assembly Biosciences? Assembly Biosciences saw a decrease in short interest in the month of February. As of February 29th, there was short interest totaling 19,600 shares, a decrease of 63.0% from the February 14th total of 53,000 shares. Based on an average trading volume of 30,800 shares, the short-interest ratio is presently 0.6 days. Currently, 0.5% of the company's stock are short sold. View Assembly Biosciences' Short Interest. When is Assembly Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our ASMB earnings forecast. How were Assembly Biosciences' earnings last quarter? Assembly Biosciences, Inc. (NASDAQ:ASMB) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($4.92) EPS for the quarter, beating analysts' consensus estimates of ($6.84) by $1.92. The biopharmaceutical company had revenue of $6.25 million for the quarter. When did Assembly Biosciences' stock split? Assembly Biosciences's stock reverse split before market open on Monday, February 12th 2024. The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is John McHutchison's approval rating as Assembly Biosciences' CEO? 8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend. What other stocks do shareholders of Assembly Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include BioDelivery Sciences International (BDSI), Exelixis (EXEL), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), AVEO Pharmaceuticals (AVEO), Sorrento Therapeutics (SRNE), AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and Blueprint Medicines (BPMC). Who are Assembly Biosciences' major shareholders? Assembly Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (42.68%), Vanguard Group Inc. (42.68%), Federated Hermes Inc. (0.46%), Acuitas Investments LLC (0.40%), Northern Trust Corp (0.20%) and Marquette Asset Management LLC (0.08%). Insiders that own company stock include Alexander Schornstein, Jason A Okazaki, Jeanette M Bjorkquist, John G Mchutchison, Luisa M Stamm, Michael P Samar, Nicole S White, Timothy A Springer, William E Iv Delaney and William E Iv Delaney. View institutional ownership trends. How do I buy shares of Assembly Biosciences? Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ASMB) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.